Oncogenically active MYD88 mutations in human lymphoma - Wikidata - thesis-toulmin - TriplyDB

Oncogenically active MYD88 mutations in human lymphoma

Oncogenically active MYD88 mutations in human lymphoma

http://www.wikidata.org/entity/Q28301648

about

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88 Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma DNA methylation screening identifies driver epigenetic events of cancer cell survival The paracaspase MALT1: biological function and potential for therapeutic inhibition Unexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesis Molecular Pathogenesis of MALT Lymphoma Tyrosine phosphorylation in Toll-like receptor signaling Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma The Yin and Yang of Toll-like receptors in cancer Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma IRAK signalling in cancer IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance The genetic landscape of diffuse large B-cell lymphoma Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib NF-κB in cellular senescence and cancer treatment The TLR and IL-1 signalling network at a glance Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia The pathogenesis of chronic lymphocytic leukemia Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection Molecular mechanisms for the subversion of MyD88 signaling by TcpC from virulent uropathogenic Escherichia coli Lessons from mathematically modeling the NF-κB pathway.Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies The Role of Toll-Like Receptors in Hematopoietic Malignancies Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4 MyD88: a central player in innate immune signaling Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

P2860

Q24294856-57FE63F9-0679-49D1-8991-11FF765788E2 Q24304887-9DF1EFE8-EF31-433A-A956-2FBF2A190331 Q24612248-F7CA9447-CD0D-4F9C-8550-5A81B59EFC27 Q24621930-E90970AD-194B-4515-A7A4-3B1CABC9E287 Q24630610-BEBF686D-66C1-4EB9-8D82-29168281BDFD Q24632287-A28450CD-D447-4C01-B1AD-291FA02E4F09 Q26778357-89122025-7452-469D-AED1-7373365FF076 Q26822486-3EF94CBD-ABBB-44AD-9D58-2DE6AF3B6965 Q26825394-0A36223D-F7E5-4668-B66D-F2E79C887BE6 Q26828015-05A67842-6BE3-488C-8A4C-E318B80F104F Q26851166-083BE58B-D15F-4919-B31F-5A9058F7575A Q26851526-674806D2-8D55-43DE-9784-ED7E0B719A72 Q26853170-4032B951-F187-4A3E-B4C5-29BA0001071A Q26863735-5AC89ED6-9981-4693-AE97-23AB40DA7EAC Q26866390-8126CF43-859A-4836-9591-6C87BD8EE010 Q26866537-6D409F50-76C7-4C5A-80CA-BA6BCBE49242 Q26991890-F2D9BFF7-7056-4E06-AEBF-D71BA68FB8DA Q26995113-4E05D996-458E-4EC3-96A0-F90762F019A5 Q27007045-E802EABC-C4F7-4866-ADBD-740D877CFC51 Q27013358-BECFF083-06DA-4330-ACF3-3912FD0B69E7 Q27013785-612D9B92-D603-4C50-93B8-85EC5674D0AA Q27024411-24E82974-4D53-45C9-9209-40BD7D7B3C7A Q27025715-108F1B98-76FF-4EEE-B0EA-0D49E21CFD92 Q27027493-3E5A709E-5297-423D-8E0C-31DE63FD9019 Q27302812-F487B1E6-253F-4DCF-9E92-488BDC370D88 Q27304386-2CDE620E-6D86-47A3-9B15-FB6D8A74DB32 Q27672321-B0D30E65-53D5-43A4-A6AC-9866E8C0376B Q27677266-226077FB-0210-42BD-8F22-7E68F387ED7E Q27690748-D5FBD891-9125-401C-B9EF-12A61DC32185 Q27851655-4FFA06BC-68B3-4EE5-AAA4-2F2EBEF09C39 Q28067817-C42C3AC0-C1D1-4130-98AD-1898E7148086 Q28077740-8B8B009E-B58F-4585-846D-500C75DB94D2 Q28078574-F3B99691-E517-45A0-90BC-7F835E2EBDF1 Q28087307-FBFCF623-7B50-44E3-9040-227B929A2384 Q28115962-6D976921-5D9C-4274-AECD-01BFBED845A7 Q28245018-7C343E05-0A76-4EF5-AF14-E504571DB206 Q28247501-4F1D617A-EA9C-4DA9-AE88-2D90435F74B9 Q28538467-A5BE77B4-C532-4445-BC67-EF203BB586FD Q28547976-BC7BA36B-72DE-4DEE-B4A5-9E4475CFD16D Q28649793-0EE9643B-7F2B-4FF1-B65B-E8F7AD0FA0CA

P2860

Oncogenically active MYD88 mutations in human lymphoma

http://www.wikidata.org/entity/Q28301648

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Oncogenically active MYD88 mutations in human lymphoma

@ast

Oncogenically active MYD88 mutations in human lymphoma

@en

Oncogenically active MYD88 mutations in human lymphoma

@nl

type

label

Oncogenically active MYD88 mutations in human lymphoma

@ast

Oncogenically active MYD88 mutations in human lymphoma

@en

Oncogenically active MYD88 mutations in human lymphoma

@nl

prefLabel

Oncogenically active MYD88 mutations in human lymphoma

@ast

Oncogenically active MYD88 mutations in human lymphoma

@en

Oncogenically active MYD88 mutations in human lymphoma

@nl

P1433

Q28301648-E6D45A82-2862-45CC-BA9A-0AFB7C18E2DD

P1476

Q28301648-CD2EB4D8-12A4-43DF-8049-3BAF98025EDF

P2093

Q28301648-033194FD-F9C8-4BE6-8A8C-3760015E2E56

Q28301648-06683291-62A7-43AB-8A7F-17374C2CD5C7

Q28301648-19C36675-C376-41A5-8DF0-17BFDE223591

Q28301648-20CE967A-8FCC-48C7-AF0E-AAAFD3DE0FA8

Q28301648-3C0A0AF4-29A2-439A-AEA1-8827BFCF70D5

Q28301648-3D1530BC-B98F-4BD2-928F-556F1F7E9FA7

Q28301648-68A10919-49A3-44E9-AA84-5B1502E2705E

Q28301648-6FC3BB05-4387-44FA-B67A-E48EE7EE21C8

Q28301648-8497EA0D-2E19-4AA4-818C-79DA33B37226

Q28301648-8B9941BD-DD0E-4E97-9FD7-67AF8728EF02

P2860

Q28301648-050BFF69-AC4C-4085-9F30-A9BD61CA0A87

Q28301648-0E1FCA74-5420-4673-962E-0A52B117820D

Q28301648-1E7431DF-5939-4BEA-8B12-CC522672F2C5

Q28301648-203EAAE0-A2C0-486E-821C-5A177A692B37

Q28301648-2CD81FB4-4D16-41A9-860C-3B58372FE6E6

Q28301648-36FE9D97-EBD0-4CB6-8C88-98510E6024BD

Q28301648-379A72FD-E5B7-4F91-8C6B-EEEC9B1A3289

Q28301648-3AA32393-903B-473C-BB0A-95385FF10A93

Q28301648-3BB2B3C4-281C-4A3D-ACF9-FC3DB1882DF8

Q28301648-4B323AD0-835D-4002-A51D-6223820ED8AF

P2888

Q28301648-2D061BC9-839A-4689-B0D6-13255450E203

P304

Q28301648-C408C94E-384B-4B24-9C01-6EE88DC89C3E

P31

Q28301648-A4A8C108-7F7F-4D47-9FF7-0B2E54FA10ED

P3181

Q28301648-30F0F54A-F53A-4EA3-8329-50EE90D413E4

P356

Q28301648-52270602-26DA-4048-B655-30BCF5B4BFC8

P407

Q28301648-C2ADD5CE-753E-40EA-9036-C7E06751AD89

P433

Q28301648-C7AC8A06-14C3-4968-B9F6-B056D7FAC8A2

P478

Q28301648-2909649A-79E2-45DD-B195-AFA69FD8159F

P50

Q28301648-00F4BC1D-CBE1-47E4-88E9-E2DB34347193

Q28301648-14C735F9-492B-4DD0-8C64-70ECE36650F7

Q28301648-1A762603-4501-4068-8512-5689BD906C01

Q28301648-260F4F68-9701-4446-9C06-9D10F76E6DAA

Q28301648-27C2DDC4-DFE6-484C-92A3-FFBF793E5DA2

Q28301648-27D26EC3-2F0D-4A22-8792-F54A64ACE30C

Q28301648-41D3B59F-DF22-43AB-9F44-B171C9952C96

Q28301648-472256EB-533D-41BB-A73E-D1528BD20751

Q28301648-89F39A80-18F1-4D38-8A32-0D7CC05C5A3A

Q28301648-8B319E54-5174-492E-BB2A-4D653E6C2BE5

P577

Q28301648-60E1FD72-C970-4B53-A7F3-47EAD6CF7DBF

P5875

Q28301648-FFA4049A-0015-4D30-9DFD-CB35F4D84830

P6179

Q28301648-ABB7D8CA-CC6F-4EF2-BEF3-218FB0682367

P698

Q28301648-A94FFAD7-0024-48EE-9B0A-C8DE154FFE6A

P932

Q28301648-AAD4EFB5-49E1-4337-8D6C-E5C6E59BA6BF

P3181

P356

P1433

P1476

Oncogenically active MYD88 mutations in human lymphoma

@en

P2093

Arthur L Shaffer

http://www.w3.org/2001/XMLSchema#string

Denny D Weisenburger

http://www.w3.org/2001/XMLSchema#string

George Wright

http://www.w3.org/2001/XMLSchema#string

Holger Kohlhammer

http://www.w3.org/2001/XMLSchema#string

Hong Zhao

http://www.w3.org/2001/XMLSchema#string

J R Cook

http://www.w3.org/2001/XMLSchema#string

John Powell

http://www.w3.org/2001/XMLSchema#string

Lisa M Rimsza

http://www.w3.org/2001/XMLSchema#string

Raymond R Tubbs

http://www.w3.org/2001/XMLSchema#string

Richard I Fisher

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for signal transduction by the Toll/interleukin-1 receptor domains

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling

Aggressive lymphomas

Stromal gene signatures in large-B-cell lymphomas

Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis.

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.

A loss-of-function RNA interference screen for molecular targets in cancer.

A library of gene expression signatures to illuminate normal and pathological lymphoid biology.

P2888

P304

115-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

936671

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE09671

http://www.w3.org/2001/XMLSchema#string

P407

P433

7332

http://www.w3.org/2001/XMLSchema#string

P478

470

http://www.w3.org/2001/XMLSchema#string

P50

Erlend B. Smeland

Hans Konrad Müller-Hermelink

Andreas Rosenwald

Joseph M Connors

Paul B. Romesser

P577

2011-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49703097

http://www.w3.org/2001/XMLSchema#string

P6179

1002056529

http://www.w3.org/2001/XMLSchema#string

P698

21179087

http://www.w3.org/2001/XMLSchema#string

P932

5024568

http://www.w3.org/2001/XMLSchema#string